1626 related articles for article (PubMed ID: 19375579)
1. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
2. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
3. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
4. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study.
Pontikis C; Yavropoulou MP; Toulis KA; Kotsa K; Kazakos K; Papazisi A; Gotzamani-Psarakou A; Yovos JG
J Womens Health (Larchmt); 2011 Jun; 20(6):971-6. PubMed ID: 21671782
[TBL] [Abstract][Full Text] [Related]
5. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
[TBL] [Abstract][Full Text] [Related]
6. Incretin levels in polycystic ovary syndrome.
Vrbikova J; Hill M; Bendlova B; Grimmichova T; Dvorakova K; Vondra K; Pacini G
Eur J Endocrinol; 2008 Aug; 159(2):121-7. PubMed ID: 18511472
[TBL] [Abstract][Full Text] [Related]
7. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
9. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
11. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
12. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
Guido M; Romualdi D; Giuliani M; Suriano R; Tienforti D; Costantini B; Lanzone A
Fertil Steril; 2005 Nov; 84(5):1470-6. PubMed ID: 16275246
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
14. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
[TBL] [Abstract][Full Text] [Related]
15. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
[TBL] [Abstract][Full Text] [Related]
17. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
[TBL] [Abstract][Full Text] [Related]
19. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]